Neurological device maker NICO and Hitachi (NYSE:HIT) said they are collaborating to create an ultrasound probe to aid in brain tumor operations using Nico’s BrainPath device.
Hitachi’s Aloka ultrasound probe, which is still being developed, will be usable with Nico’s BrainPath device to allow operators better visualization of the location, size, and proximity of vessels during resection operations, the company said.
“The new Hitachi Aloka ultrasound probe provides real-time intraoperative imaging feedback with the economics and efficiency of an ultrasound. With the immediate feedback it provides surgeons within a minimally invasive corridor, they can confirm location of the brain tumor, proximity of nearby vessels that may be encountered beyond the direct field of view and confirms the extent of the resection,” Dr. Juan Alzate of the American Center for Spine and Neurosurgery and Cancer Treatment Centers of America in Chicago said in prepared remarks.
Last month, NICO announced that it won FDA 501(k) clearance for indications of subcortical access to brain tumors, cysts and vascular diseases, the company said.
“This complementary imaging tool is an important advancement in visualization for subcortical surgery. The neurosurgical field is rapidly adopting new devices to expand treatment capabilities as the population ages and the number of cases increase. BrainPath is at the center of this growth due to its ability to uniquely provide atraumatic subcortical access, providing a platform for other innovative, neurosurgical device companies to partner with us in creating better options for patients. What we are seeing is expansion of the addressable market in neurosurgery right before our eyes.” NICO CEO Jim Pearson said in a press release.
“For a field as complex as neurosurgery, we are excited to partner with NICO on this innovative new solution for minimally invasive, yet highly effective surgical site visualization and access. Ultimately, our goal is to provide patients with brain abnormalities both better and safer options for treatment,” Hitachi Aloka Medical America prez David Famiglietti said in a prepared statement.
